Cardiff Oncology, Inc. Board of Directors

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Ms. Brigitte Lindsay

Ms. Brigitte Lindsay

Senior Vice President of Finance

Dr. Tod Smeal Ph.D.

Dr. Tod Smeal Ph.D.

Chief Scientific Officer

Mr. James E. Levine

Mr. James E. Levine

Chief Financial Officer

Mr. Charles Monahan R.Ph.

Mr. Charles Monahan R.Ph.

Senior Vice President of Regulatory Affairs

Ms. Elizabeth Anderson

Ms. Elizabeth Anderson

VP of Finance & Administration

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.